Ruxolitinib for myelofibrosis--an update of its clinical effects. - Wikidata - wikimedia - TriplyDB

Ruxolitinib for myelofibrosis--an update of its clinical effects.

Ruxolitinib for myelofibrosis--an update of its clinical effects.

http://www.wikidata.org/entity/Q33411502

about

Managing Patients With Myelofibrosis in the Era of Janus Kinase Inhibitors Going for broke: targeting the human cancer pseudokinome.Re-examining HSPC1 inhibitors.Calreticulin mutant mice develop essential thrombocythemia that is ameliorated by the JAK inhibitor ruxolitinib Long-term effects of ruxolitinib versus best available therapy on bone marrow fibrosis in patients with myelofibrosis.Modulation of bone marrow microenvironment following ruxolitinib therapy in myelofibrosis.Classical Philadelphia-negative myeloproliferative neoplasms: focus on mutations and JAK2 inhibitors

P2860

Q28073296-0E0367E6-692B-4317-935A-0D8A4B789822 Q38307398-1A9E9204-EEC8-44FA-9FFD-8F485D05D193 Q38931732-E7720408-1809-4098-BE27-98B14C52C631 Q41955541-2F5F8846-798D-4991-BBD9-8957DADBE308 Q51733623-F691431B-2810-4523-82D9-B0530E709C8E Q54250506-6F03AF99-CCA5-4C49-9093-1A5CCBFABC0C Q58801187-D974F72C-C5D0-420A-A788-BF92B937DA18

P2860

Ruxolitinib for myelofibrosis--an update of its clinical effects.

http://www.wikidata.org/entity/Q33411502

description

2013 nî lūn-bûn

@nan

2013 թուականի Հոկտեմբերին հրատարակուած գիտական յօդուած

@hyw

2013 թվականի հոտեմբերին հրատարակված գիտական հոդված

@hy

2013年の論文

@ja

2013年論文

@yue

2013年論文

@zh-hant

2013年論文

@zh-hk

2013年論文

@zh-mo

2013年論文

@zh-tw

2013年论文

@wuu

name

Ruxolitinib for myelofibrosis--an update of its clinical effects.

@ast

Ruxolitinib for myelofibrosis--an update of its clinical effects.

@en

type

label

Ruxolitinib for myelofibrosis--an update of its clinical effects.

@ast

Ruxolitinib for myelofibrosis--an update of its clinical effects.

@en

prefLabel

Ruxolitinib for myelofibrosis--an update of its clinical effects.

@ast

Ruxolitinib for myelofibrosis--an update of its clinical effects.

@en

P1433

Q33411502-E0A9418F-7C7B-499B-A21B-CD9A4B05CF28

P1476

Q33411502-BBB49ADE-FDE2-4F76-B295-1D3787A67241

P2093

Q33411502-06311734-51DC-49E6-BFD6-E4E89416D010

Q33411502-2E98FA33-2759-42E0-87D4-C378545BE670

Q33411502-4E92E0CD-E3B3-47C8-8C0E-D939FE2D68F1

Q33411502-6C421BE2-8F68-436B-8192-CAA270E5E142

Q33411502-F3F3F1A4-FAE6-4DBF-9314-8E511D5EC235

P2860

Q33411502-07E3269E-42EF-4E16-9D42-2B32242F261C

Q33411502-143E735A-9738-4E29-9CAE-CAA698C93DE7

Q33411502-22A47BFB-CA30-4D2F-9A04-06D292696BDE

Q33411502-2303397D-A20D-4D33-82A0-CF9EEC78BA11

Q33411502-30F14062-BC26-4064-9B8B-73B7BAEA8860

Q33411502-35B58AD8-A9B4-4D1D-89AB-E1692294F560

Q33411502-4B7709D8-930B-4AE0-92D1-D11AC8536D2A

Q33411502-54929495-E8FD-499E-A2CA-8E1948187E9C

Q33411502-59C9E652-E826-411E-AB18-0F3E05E15A57

Q33411502-5E65615C-8023-426E-AA3B-5B16A00A8952

P304

Q33411502-B6A6063D-E112-4086-B32D-63DA954FE7F2

P31

Q33411502-C6F69D08-70F7-4EDF-B7E6-8E9E21E31C86

P356

Q33411502-05EAB7F5-38E0-452F-B8F6-CD34627890A5

P407

Q33411502-346E892C-41B9-4F6F-85DB-2EAA4736BAF4

P433

Q33411502-E2AE89B5-D480-4693-91A4-1D63474C7A38

P478

Q33411502-5A81A3CA-F001-4920-92C0-6A8AA446B469

P50

Q33411502-2B19BFF5-3D77-4C2E-8AB9-E11A834A9CC2

P577

Q33411502-D219B58E-DC75-4B68-BBC7-0FE5CD17DF3B

P5875

Q33411502-50D9C118-CAF3-4209-99FA-6F6669909CF7

P698

Q33411502-1F074C76-D72C-483B-86E9-4FEB39AFCC7A

P932

Q33411502-F1B41186-CF8C-4B44-BBF2-D0417C212957

P356

J.CLML.2013.09.006

P1433

Clinical Lymphoma, Myeloma & Leukemia

P1476

Ruxolitinib for myelofibrosis--an update of its clinical effects.

@en

P2093

Claire N Harrison

http://www.w3.org/2001/XMLSchema#string

Rami S Komrokji

http://www.w3.org/2001/XMLSchema#string

Richard T Silver

http://www.w3.org/2001/XMLSchema#string

Roland Tacke

http://www.w3.org/2001/XMLSchema#string

Ruben A Mesa

http://www.w3.org/2001/XMLSchema#string

P2860

Novel mutations and their functional and clinical relevance in myeloproliferative neoplasms: JAK2, MPL, TET2, ASXL1, CBL, IDH and IKZF1

The Jak-Stat pathway in normal and perturbed hematopoiesis

Safety and efficacy of INCB018424, a JAK1 and JAK2 inhibitor, in myelofibrosis.

DIPSS plus: a refined Dynamic International Prognostic Scoring System for primary myelofibrosis that incorporates prognostic information from karyotype, platelet count, and transfusion status.

Serious adverse events during ruxolitinib treatment discontinuation in patients with myelofibrosis.

JAK inhibition with ruxolitinib versus best available therapy for myelofibrosis.

A double-blind, placebo-controlled trial of ruxolitinib for myelofibrosis.

Effect of ruxolitinib therapy on myelofibrosis-related symptoms and other patient-reported outcomes in COMFORT-I: a randomized, double-blind, placebo-controlled trial.

Impact of JAK2 V617F mutation on hemogram variation in patients with non-reactive elevated platelet counts

Proposals and rationale for revision of the World Health Organization diagnostic criteria for polycythemia vera, essential thrombocythemia, and primary myelofibrosis: recommendations from an ad hoc international expert panel.

P304

638-645

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1016/J.CLML.2013.09.006

http://www.w3.org/2001/XMLSchema#string

P407

P433

6

http://www.w3.org/2001/XMLSchema#string

P478

13

http://www.w3.org/2001/XMLSchema#string

P50

Hagop Kantarjian

P577

2013-10-02T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

258633723

http://www.w3.org/2001/XMLSchema#string

P698

24238036

http://www.w3.org/2001/XMLSchema#string

P932

5556922

http://www.w3.org/2001/XMLSchema#string